糖尿病患者与非糖尿病患者在接受心肌灌注单光子发射计算机断层扫描后血运重建与药物治疗的长期生存获益比较
研究纳入1998至2017年接受负荷和静息SPECT-MPI的41982例患者,其中8328例(19.8%)有糖尿病,倾向性评分匹配后糖尿病与非糖尿病各8046例。中位随访10.3年,糖尿病组年化死亡率高于非糖尿病组(4.7% vs 3.6%,P<0.001)。早期血运重建的生存获益在糖尿病患者中缺血阈值>8.6%时出现,非糖尿病患者阈值>12.1%。
要点
- 糖尿病患者年化死亡率高于非糖尿病者(4.7% vs 3.6%,P<0.001)。
- 早期血运重建的生存获益在糖尿病者缺血>8.6%时出现,非糖尿病者>12.1%。
- 使用胰岛素的糖尿病患者死亡率更高(6.2% vs 4.1%,P<0.001)。
核心结论
- 糖尿病患者尤其使用胰岛素者死亡率高于非糖尿病患者。
- 早期血运重建在糖尿病患者中于较低缺血阈值即与死亡获益相关,该阈值低于非糖尿病患者。
研究设计与样本
- 大型观察性队列研究,纳入1998至2017年接受负荷和静息SPECT-MPI的41982例患者,其中8328例(19.8%)有糖尿病。
- 采用倾向性评分将8046例糖尿病患者与8046例非糖尿病患者匹配。
- 早期血运重建定义为SPECT-MPI后90天内进行。
- 心肌缺血百分比通过SPECT-MPI上可逆性心肌灌注缺损的程度评估。
主要发现
- 中位随访10.3年,糖尿病组年化死亡率为4.7%,非糖尿病组为3.6%(P<0.001)。
- 早期血运重建与心肌缺血百分比在糖尿病和非糖尿病患者中均存在显著交互作用(所有交互P值<0.05)。
- 调整混杂变量后,糖尿病患者在缺血>8.6%时观察到早期血运重建的生存获益,非糖尿病患者在缺血>12.1%时观察到生存获益。
- 使用胰岛素的糖尿病患者死亡率高于未使用胰岛素者(6.2% vs 4.1%,P<0.001),但血运重建与胰岛素使用之间无交互作用(交互P值=0.405)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the long-term association of survival benefit from early revascularization with the magnitude of ischemia in patients with diabetes compared with those without diabetes using a large observational cohort of patients undergoing single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI). RESEARCH DESIGN AND METHODS: Of 41,982 patients who underwent stress and rest SPECT-MPI from 1998 to 2017, 8,328 (19.8%) had diabetes. A propensity score was used to match 8,046 patients with diabetes to 8,046 patients without diabetes. Early revascularization was defined as occurring within 90 days after SPECT-MPI. The percentage of myocardial ischemia was assessed from the magnitude of reversible myocardial perfusion defect on SPECT-MPI. RESULTS: Over a median 10.3-year follow-up, the annualized mortality rate was higher for the patients with diabetes compared with those without diabetes (4.7 vs. 3.6%; P < 0.001). There were significant interactions between early revascularization and percent myocardial ischemia in patients with and without diabetes (all interaction P values <0.05). After adjusting for confounding variables, survival benefit from early revascularization was observed in patients with diabetes above a threshold of >8.6% ischemia and in patients without diabetes above a threshold of >12.1%. Patients with diabetes receiving insulin had a higher mortality rate (6.2 vs. 4.1%; P < 0.001), but there was no interaction between revascularization and insulin use (interaction P value = 0.405). CONCLUSIONS: Patients with diabetes, especially those on insulin treatment, had higher mortality rate compared with patients without diabetes. Early revascularization was associated with a mortality benefit at a lower ischemic threshold in patients with diabetes compared with those without diabetes.
引用
- Kuronuma K, Han D, Miller RJH, et al. Long-term Survival Benefit From Revascularization Compared With Medical Therapy in Patients With or Without Diabetes Undergoing Myocardial Perfusion Single Photon Emission Computed Tomography. Diabetes Care. 2022. PMID: 36001757. doi:10.2337/dc22-0454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。